Corvus Pharmaceuticals Files 8-K

TL;DR

CRVS filed an 8-K, mostly standard financial updates.

AI Summary

On January 13, 2025, Corvus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, without specifying any new material developments or financial figures in the provided text.

Why It Matters

This filing indicates Corvus Pharmaceuticals is providing updated financial statements and exhibits, which is a standard regulatory requirement for public companies.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any significant new risks or material adverse events.

Key Players & Entities

• Corvus Pharmaceuticals, Inc. (company) — Registrant
• January 13, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market

Filing Documents

• crvs-20250113x8k.htm (8-K) — 48KB
• crvs-20250113xex99d1.htm (EX-99.1) — 26KB
• crvs-20250113x8k006.jpg (GRAPHIC) — 41KB
• crvs-20250113xex99d1001.jpg (GRAPHIC) — 5KB
• crvs-20250113xex99d1002.jpg (GRAPHIC) — 41KB
• 0001558370-25-000150.txt ( ) — 361KB
• crvs-20250113.xsd (EX-101.SCH) — 3KB
• crvs-20250113_lab.xml (EX-101.LAB) — 15KB
• crvs-20250113_pre.xml (EX-101.PRE) — 10KB
• crvs-20250113x8k_htm.xml (XML) — 5KB

01. Regulation FD

Item 7.01. Regulation FD. On January 13, 2025, Corvus Pharmaceuticals, Inc. (the "Company") issued the press release furnished as Exhibit 99.1 hereto.

01. Other Events

Item 8.01. Other Events. On January 13, 2025, the Company announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. Soquelitinib Interim Data from the Atopic Dermatitis Phase 1 Clinical Trial The Company is reporting results from 16 patients in Cohort 1 (12 patients in the soquelitinib group receiving 100 mg orally twice per day vs. four receiving placebo) and 10 patients in Cohort 2 (seven patients in the soquelitinib group receiving 200 mg orally once per day vs. three receiving placebo) for which 28 days of treatment have been completed. For those 19 patients in the soquelitinib group, 26% achieved IGA 0 or 1 and 37% achieved EASI 75; and of the seven in the placebo group, none achieved IGA 0 or 1 or EASI 75 (see Figure 1 below). IGA 0 or 1 and EASI 75 have been determined by the U.S. Food and Drug Administration (FDA) to be clinically meaningful and approvable endpoints and have been the endpoints used in clinical trials for other FDA approved treatments for atopic dermatitis. No significant safety issues were observed and no clinically significant laboratory abnormalities were seen. All 10 patients from Cohort 2 completed 28 days of dosing at the full dose of 200 mg orally once per day; the remaining patients from Cohort 2 are at various stages of treatment. Cohort 2 of the trial is fully enrolled (N=16) and the Company plans to report full results from all four study cohorts in the second quarter 2025. Figure 1: Percent Patients Achieving Endpoints IGA 0 or 1, EASI 75 at Day 28 of Treatment The placebo patients from Cohort 1 (n=4) and Cohort 2 (n=3) are combined. Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Design The randomized, double-blind, placebo-controlled Phase 1 clinical trial is planned to enroll 64 patients with moderate to severe atopic dermatitis that previously failed one prior topical or systemic thera

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements, including statements related to the potential safety and efficacy of soquelitinib; and the Company's conduct of, enrollment in and timing of clinical trials and results. All statements other than statements of historical fact contained in this Current Report on Form 8-K are forward-looking statements. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, filed with the Securities and Exchange Commission on November 12, 2024, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company's ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company's estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company's ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and other foreign countries; the

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Corvus Pharmaceuticals, Inc. dated January 13, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL Document). The information furnished in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORVUS PHARMACEUTICALS, INC. Date: January 13, 2025 By: /s/ Leiv Lea Leiv Lea Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR